Efficacy and safety of tranexamic acid in the treatment of gastric cancer complicated with upper gastrointestinal bleeding.

Autor:	Bai Z; Emergency Department, The Fourth Hospital of Hebei Medical University Shijiazhuang 050000, Hebei, China., Wang L; Emergency Department, The Fourth Hospital of Hebei Medical University Shijiazhuang 050000, Hebei, China., Yu B; Emergency Department, The Fourth Hospital of Hebei Medical University Shijiazhuang 050000, Hebei, China., Xing D; Emergency Department, The Fourth Hospital of Hebei Medical University Shijiazhuang 050000, Hebei, China., Su J; Emergency Department, The Fourth Hospital of Hebei Medical University Shijiazhuang 050000, Hebei, China., Qin H; Emergency Department, The Fourth Hospital of Hebei Medical University Shijiazhuang 050000, Hebei, China.
Jazyk:	angličtina
Zdroj:	American journal of translational research [Am J Transl Res] 2024 Mar 15; Vol. 16 (3), pp. 925-932. Date of Electronic Publication: 2024 Mar 15 (Print Publication: 2024).
DOI:	10.62347/KOLI5819
Abstrakt:	Objective: To investigate the efficacy and safety of tranexamic acid (TXA) in preventing upper gastrointestinal (GI) bleeding in patients with gastric cancer. Methods: The clinical data of patients with gastric cancer complicated with acute non-operative GI bleeding treated in the Fourth Hospital of Hebei Medical University from 2020 to 2022 were collected and retrospectively analyzed. The survival status of the patients was followed up by telephone. The dataset of 168 patients was divided into a control group (n=85) and a TXA group (n=83), at a 1:1 ratio. The patients in the control group were treated with esomeprazole, and the patients in the TXA group received additional TXA. The hemostatic effect, rebleeding rate, and mortality of patients were compared between the two groups. The Cox proportional hazard model was used to evaluate the overall survival of patients as well as the related risk factors. Results: The success rate of hemostasis and the normal blood coagulation rate in the TXA group were significantly higher than those in the control group (P=0.003 and P=0.016). The secondary bleeding rate, thrombus formation rate and digestive tract perforation rate in the TXA group were significantly lower than those in the control group (P=0.002, P=0.003 and P=0.035). The improvement of all indicators in the TXA group was better than that in the control group (all P<0.05). For patients with gastric cancer complicated with acute GI bleeding treated with TXA, the Cox proportional hazard model identified III~IV stage, time of TXA treatment, surgical treatment after hemorrhage, and an increase of D-dimer as independent risk factors for upper GI bleeding (all P<0.05). Conclusion: TXA can be an effective treatment for patients with gastric cancer complicated by GI bleeding. Competing Interests: None. (AJTR Copyright © 2024.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu